NCT05680740

A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis

A Phase 4, Open-label, Study to Investigate the Efficacy and Safety of VTAMA® (Tapinarof) Cream 1% in the Treatment of Plaque Psoriasis in Intertriginous Areas

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multi-center study to evaluate the efficacy and safety of VTAMA (tapinarof) cream, 1% in adults with intertriginous psoriasis

Detailed description

This is an open-label study in which participants will be assigned to receive VTAMA (tapinarof) cream, 1% once daily for 12 weeks. Study participants will have a follow-up period of 1 week. The study duration will be up to 17 weeks.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	VTAMA® (tapinarof) Cream 1%	VTAMA® (tapinarof) Cream 1% applied topically once daily

Timeline

• Start date: 2022-12-27
• Primary completion: 2023-05-18
• Completion: 2023-05-25
• First posted: 2023-01-11
• Last updated: 2025-06-12
• Results posted: 2024-07-08

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study